Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Clinical trial NCT03252938 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03252938
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors Peritoneal Carcinomatosis NSCLC Adenocarcinoma Urothelial Carcinoma

Start date: 2017-08-15
Primary completion: 2026-09-30
Enrollment: 83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.